PharmaMar enrolls First Patient in Phase 1/2 Trial Evaluating PM54 Plus Pembrolizumab in Advanced Solid Tumors

PharmaMar (MSE: PHM) has announced the enrollment of the first patient in its Phase 1/2 clinical trial evaluating PM54 in combination with pembrolizumab for the treatment of patients with advanced-stage solid tumors. The study, for which the IND application was cleared by the FDA in December 2025, is designed to assess the safety, tolerability, and preliminary efficacy of this combination therapy in patients with previously treated advanced malignancies. The primary objectives of the study include the evaluation of the safety and tolerability of PM54 in combination with pembrolizumab and to establish the recommended dose, as well as the assessment of the antitumor activity, in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator evaluation. The study includes patients with tumors characterized by significant unmet medical needs, including advanced-stage melanoma, endometrial cancer, extrapulmonary neuroendocrine tumors and mesothelioma. For more information on the study, please visit clinicaltrials.gov PM54 in combination with pembrolizumab is intended to enhance antitumor immune responses and provide a potential new treatment option for patients with advanced-stage solid tumors.

The release as fetched from its publisher. pharmamar.com ↗